Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023319 · ClinicalTrials.gov registry record · Phase 1
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Bladder Cancer, sponsored by Nagla Abdel Karim.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03023319: Completed Phase 1 study of Ovarian Cancer and Bladder Cancer, sponsored by Nagla Abdel Karim.
NCT03023319 is a Phase 1 study of Ovarian Cancer and Bladder Cancer that has completed, run by Nagla Abdel Karim. The registered enrollment target is 6 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03023319, a Phase 1 study of Ovarian Cancer and Bladder Cancer, has completed, sponsored by Nagla Abdel Karim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Primary Outcome
CTCAE Grade 3 or 4 non-hematologic toxicities other than alopecia, nausea and vomiting.
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Bosutinib
Study Locations (1)
Georgia
- Augusta University Georgia Cancer Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 1 |
What the finished NCT03023319 record still lists
NCT03023319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower).
The record links to 8 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pemetrexed is the first listed.
NCT03023319 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03023319 about?
NCT03023319 is a clinical study titled "Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors". This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see wha...
What is the current status of trial NCT03023319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-12-10. Estimated completion is 2022-05-10.
What conditions does trial NCT03023319 study?
This clinical trial studies the following conditions: Ovarian Cancer, Bladder Cancer, Carcinoma, Non-Small Cell Lung, Mesothelioma, Peritoneal Cancer.
What interventions are being tested in trial NCT03023319?
The interventions under investigation include: Pemetrexed (DRUG), Bosutinib (DRUG).
Who is sponsoring clinical trial NCT03023319?
This trial is sponsored by Nagla Abdel Karim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03023319 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03023319's enrollment target sits among peer trials
6 316th of 322 higher than 6 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI